Disruption of striatal-enriched protein tyrosine phosphatase (STEP) function in neuropsychiatric disorders

Neuroscience Research

Volumn 89, Issue , 2014, Pages 1-9

  Karasawa, Takatoshi ^a   Lombroso, Paul J ^b  

^a INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Fragile x syndrome; Huntington's disease; Schizophrenia; STEP; Stroke

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PTPN5 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; ENDOPLASMIC RETICULUM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; INTERNALIZATION; LONG TERM POTENTIATION; MENTAL DISEASE; MOLECULAR BIOLOGY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; OLIGOMERIZATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; STRESS; ANIMAL; BRAIN; ENZYMOLOGY; MENTAL STRESS; METABOLISM; NERVE CELL PLASTICITY; PHOSPHORYLATION; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; BRAIN ISCHEMIA; COGNITION; FRAGILE X SYNDROME; HUMANS; HUNTINGTON DISEASE; MENTAL DISORDERS; NEURONAL PLASTICITY; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL; STROKE;

EID: 84919419577     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2014.08.018     Document Type: Review

References (101)

1. Adachi M., Sekiya M., Arimura Y., Takekawa M., Itoh F., Hinoda Y., Imai K., Yachi A. Protein-tyrosine phosphatase expression in pre-B cell NALM-6. Cancer Res. 1992, 52:737-740.
2. Antar L.N., Bassell G.J. Sunrise at the synapse: the FMRP mRNP shaping the synaptic interface. Neuron 2003, 37:555-558.
3. Aronowski J., Strong R., Grotta J.C. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J. Cereb. Blood Flow Metab. 1997, 17:1048-1056.
4. Baguley T.D., Xu H.C., Chatterjee M., Nairn A.C., Lombroso P.J., Ellman J.A. Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase. J. Med. Chem. 2013, 56:7636-7650.
5. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
6. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
7. Blanpied T.A., Ehlers M.D. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Biol. Psychiatry 2004, 55:1121-1127.
8. Boehm J. A 'danse macabre': tau and Fyn in STEP with amyloid beta to facilitate induction of synaptic depression and excitotoxicity. Eur. J. Neurosci. 2013, 37:1925-1930.
9. Boulanger L.M., Lombroso P.J., Raghunathan A., During M.J., Wahle P., Naegele J.R. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J. Neurosci. 1995, 15:1532-1544.
10. Braithwaite S.P., Xu J., Leung J., Urfer R., Nikolich K., Oksenberg D., Lombroso P.J., Shamloo M. Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia. Eur. J. Neurosci. 2008, 27:2444-2452.
11. Briggs S.W., Walker J., Asik K., Lombroso P., Naegele J., Aaron G. STEP regulation of seizure thresholds in the hippocampus. Epilepsia 2011, 52:497-506.
12. Brouillette, J. Ménard, C., Quirion, R., Bontempi, B., Schneider, J.S., Norris, C.M., Ferland, G., Bézard, E., Gaudreau, P., Lombroso, P.J. The tyrosine phosphatase STEP is implicated in age-related memory decline across different species. (under review).
13. Bult A., Zhao F., Dirkx R., Sharma E., Lukacsi E., Solimena M., Naegele J.R., Lombroso P.J. STEP61: a member of a family of brain-enriched PTPs is localized to the endoplasmic reticulum. J. Neurosci. 1996, 16:7821-7831.
14. Carlyle B.C., Nairn A.C., Wang M., Yang Y., Jin L.E., Simen A.A., Ramos B.P., Bordner K.A., Craft G.E., Davies P., Pletikos M., Sestan N., Arnsten A.F., Paspalas C.D. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:5036-5041.
15. Carty N.C., Xu J., Kurup P., Brouillette J., Goebel-Goody S.M., Austin D.R., Yuan P., Chen G., Correa P.R., Haroutunian V., Pittenger C., Lombroso P.J. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl. Psychiatry 2012, 2:e137.
16. Chen X., Mariappan S.V., Catasti P., Ratliff R., Moyzis R.K., Laayoun A., Smith S.S., Bradbury E.M., Gupta G. Hairpins are formed by the single DNA strands of the fragile X triplet repeats: structure and biological implications. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5199-5203.
17. Chin J., Palop J.J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:9694-9703.
18. Chiodi V., Mallozzi C., Ferrante A., Chen J.F., Lombroso P.J., Di Stasi A.M., Popoli P. Cocaine-induced changes of synaptic transmission in the striatum are modulated by adenosine A2A receptors and involve the tyrosine phosphatase STEP. Neuropsychopharmacology 2014, 39:569-578.
19. Cornish K., Turk J., Hagerman R. The fragile X continuum: new advances and perspectives. J. Intellect. Disabil. Res. 2008, 52:469-482.
20. Darcq E., Hamida S.B., Wu S., Phamluong K., Kharazia V., Xu J., Lombroso P., Ron D. Inhibition of striatal-enriched tyrosine phosphatase 61 in the dorsomedial striatum is sufficient to increased ethanol consumption. J. Neurochem. 2014, 129:1024-1034.
21. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., Licatalosi D.D., Richter J.D., Darnell R.B. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
22. Deb I., Manhas N., Poddar R., Rajagopal S., Allan A.M., Lombroso P.J., Rosenberg G.A., Candelario-Jalil E., Paul S. Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia. J. Neurosci. 2013, 33:17814-17826.
23. Deb I., Poddar R., Paul S. Oxidative stress-induced oligomerization inhibits the activity of the non-receptor tyrosine phosphatase STEP61. J. Neurochem. 2011, 116:1097-1111.
24. Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996, 383:547-550.
25. Dwivedi Y., Pandey G.N. Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr. Dis. Treat. 2008, 4:161-176.
26. Dabrowska J., Hazra R., Guo J.D., Li C., Dewitt S., Xu J., Lombroso P.J., Rainnie D.G. Striatal-enriched protein tyrosine phosphatase-STEPs toward understanding chronic stress-induced activation of corticotrophin releasing factor neurons in the rat bed nucleus of the stria terminalis. Biol. Psychiatry. 2013, 74:817-826.
27. Fiala J.C., Spacek J., Harris K.M. Dendritic spine pathology: cause or consequence of neurological disorders?. Brain Res. Brain Res. Rev. 2002, 39:29-54.
28. Forlenza O.V., Diniz B.S., Gattaz W.F. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med. 2010, 8:89.
29. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999, 842:92-100.
30. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 2000, 157:1141-1149.
31. Garner C.C., Wetmore D.Z. Synaptic pathology of Down syndrome. Adv. Exp. Med. Biol. 2012, 970:451-468.
32. Giralt A., Saavedra A., Carreton O., Xifro X., Alberch J., Perez-Navarro E. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 2011, 20:4232-4247.
33. Gladding C.M., Sepers M.D., Xu J., Zhang L.Y., Milnerwood A.J., Lombroso P.J., Raymond L.A. Calpain and striatal-enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum. Mol. Genet. 2012, 21:3739-3752.
34. Goebel-Goody S.M., Baum M., Paspalas C.D., Fernandez S.M., Carty N.C., Kurup P., Lombroso P.J. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 2012, 64:65-87.
35. Goebel-Goody S.M., Wilson-Wallis E.D., Royston S., Tagliatela S.M., Naegele J.R., Lombroso P.J. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 2012, 11:586-600.
36. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001, 158:1367-1377.
37. Green A.R. Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br. J. Pharmacol. 2008, 153(Suppl. 1):S325-S338.
38. Gross C., Nakamoto M., Yao X., Chan C.B., Yim S.Y., Ye K., Warren S.T., Bassell G.J. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 2010, 30:10624-10638.
39. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
40. Hendriks W.J., Dilaver G., Noordman Y.E., Kremer B., Fransen J.A. PTPRR protein tyrosine phosphatase isoforms and locomotion of vesicles and mice. Cerebellum 2009, 8:80-88.
41. Hicklin T.R., Wu P.H., Radcliffe R.A., Freund R.K., Goebel-Goody S.M., Correa P.R., Proctor W.R., Lombroso P.J., Browning M.D. Alcohol inhibition of the NMDA receptor function, long-term potentiation, and fear learning requires striatal-enriched protein tyrosine phosphatase. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:6650-6655.
42. Hou L., Antion M.D., Hu D., Spencer C.M., Paylor R., Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006, 51:441-454.
43. Huang Y., Lu W., Ali D.W., Pelkey K.A., Pitcher G.M., Lu Y.M., Aoto H., Roder J.C., Sasaki T., Salter M.W., MacDonald J.F. CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 2001, 29:485-496.
44. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7746-7750.
45. Huttenlocher P.R. Dendritic and synaptic pathology in mental retardation. Pediatr. Neurol. 1991, 7:79-85.
46. Ibrahim H.M., Hogg A.J., Healy D.J., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry 2000, 157:1811-1823.
47. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
48. Jia Z., Agopyan N., Miu P., Xiong Z., Henderson J., Gerlai R., Taverna F.A., Velumian A., MacDonald J., Carlen P., Abramow-Newerly W., Roder J. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron 1996, 17:945-956.
49. Kim J.H., Anwyl R., Suh Y.H., Djamgoz M.B., Rowan M.J. Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 2001, 21:1327-1333.
50. Kojima N., Wang J., Mansuy I.M., Grant S.G., Mayford M., Kandel E.R. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4761-4765.
51. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
52. Kuroda S., Siesjo B.K. Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clin. Neurosci. 1997, 4:199-212.
53. Kurup P., Xu J., Ononenyi C., Nairn A.C., Lombroso C. Role of striatal-enriched protein tyrosine phosphatase (STEP) in Parkinson's disease. Poster 2012, SFN, Washington, 44.10/C65.
54. Kurup P., Zhang Y., Xu J., Venkitaramani D.V., Haroutunian V., Greengard P., Nairn A.C., Lombroso P.J. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J. Neurosci. 2010, 30:5948-5957.
55. Kurup, P., Xu, J., Videira, R.A., Ononenyi, C., Baltazar, G., Nairn, A.C., Lombroso, P.J., 2000. Role of striatal-enriched protein tyrosine phosphatase (STEP) in Parkinson's disease. (under review).
56. Kutsuwada T., Sakimura K., Manabe T., Takayama C., Katakura N., Kushiya E., Natsume R., Watanabe M., Inoue Y., Yagi T., Aizawa S., Arakawa M., Takahashi T., Nakamura Y., Mori H., Mishina M. Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron 1996, 16:333-344.
57. Kwiatkowski T.G., Libman R.B., Frankel M., Tilley B.C., Morgenstern L.B., Lu M., Broderick J.P., Lewandowski C.A., Marler J.R., Levine S.R., Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med. 1999, 340:1781-1787.
58. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24:10191-10200.
59. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci. 2004, 24:2304-2312.
60. Li Z., Zhang Y., Ku L., Wilkinson K.D., Warren S.T., Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001, 29:2276-2283.
61. Lombroso P.J., Murdoch G., Lerner M. Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:7242-7246.
62. Lorber B., Berry M., Hendriks W., den Hertog J., Pulido R., Logan A. Stimulated regeneration of the crushed adult rat optic nerve correlates with attenuated expression of the protein tyrosine phosphatases RPTPalpha, STEP, and LAR. Mol. Cell. Neurosci. 2004, 27:404-416.
63. Lu R., Wang H., Liang Z., Ku L., O'Donnell W.T., Li W., Warren S.T., Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15201-15206.
64. Luscher C., Huber K.M. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 2010, 65:445-459.
65. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
66. Mazzucchelli C., Vantaggiato C., Ciamei A., Fasano S., Pakhotin P., Krezel W., Welzl H., Wolfer D.P., Pages G., Valverde O., Marowsky A., Porrazzo A., Orban P.C., Maldonado R., Ehrengruber M.U., Cestari V., Lipp H.P., Chapman P.F., Pouyssegur J., Brambilla R. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 2002, 34:807-820.
67. Moult P.R., Gladding C.M., Sanderson T.M., Fitzjohn S.M., Bashir Z.I., Molnar E., Collingridge G.L. Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J. Neurosci. 2006, 26:2544-2554.
68. Nguyen T.H., Liu J., Lombroso P.J. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J. Biol. Chem. 2002, 277:24274-24279.
69. Nguyen T.H., Paul S., Xu Y., Gurd J.W., Lombroso P.J. Calcium-dependent cleavage of striatal enriched tyrosine phosphatase (STEP). J. Neurochem. 1999, 73:1995-2001.
70. Oberle I., Rousseau F., Heitz D., Kretz C., Devys D., Hanauer A., Boue J., Bertheas M.F., Mandel J.L. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 1991, 252:1097-1102.
71. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
72. Okamura A., Goto S., Nishi T., Yamada K., Yoshikawa M., Ushio Y. Postnatal ontogeny of striatal-enriched protein tyrosine phosphatase (STEP) in rat striatum. Exp. Neurol. 1997, 145:228-234.
73. Olausson P., Venkitaramani D.V., Moran T.D., Salter M.W., Taylor J.R., Lombroso P.J. The tyrosine phosphatase STEP constrains amygdala-dependent memory formation and neuroplasticity. Neuroscience 2012, 225:1-8.
74. Oyama T., Goto S., Nishi T., Sato K., Yamada K., Yoshikawa M., Ushio Y. Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: a light and electron microscopic study with a complementary DNA-generated polyclonal antibody. Neuroscience 1995, 69:869-880.
75. Paul S., Nairn A.C., Wang P., Lombroso P.J. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat. Neurosci. 2003, 6:34-42.
76. Paul S., Olausson P., Venkitaramani D.V., Ruchkina I., Moran T.D., Tronson N., Mills E., Hakim S., Salter M.W., Taylor J.R., Lombroso P.J. The striatal-enriched protein tyrosine phosphatase gates long-term potentiation and fear memory in the lateral amygdala. Biol. Psychiatry 2007, 61:1049-1061.
77. Paul S., Snyder G.L., Yokakura H., Picciotto M.R., Nairn A.C., Lombroso P.J. The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J. Neurosci. 2000, 20:5630-5638.
78. Pelov I., Teltsh O., Greenbaum L., Rigbi A., Kanyas-Sarner K., Lerer B., Lombroso P., Kohn Y. Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition. Psychiatr. Genet. 2012, 22:168-176.
79. Pulido R., Zuniga A., Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 1998, 17:7337-7350.
80. Raghunathan A., Matthews G.A., Lombroso P.J., Naegele J.R. Transient compartmental expression of a family of protein tyrosine phosphatases in the developing striatum. Brain Res. Dev. Brain Res. 1996, 91:190-199.
81. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
82. Rosenbaum G., Cohen B.D., Luby E.D., Gottlieb J.S., Yelen D. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. AMA Arch. Gen. Psychiatry 1959, 1:651-656.
83. Saavedra A., Giralt A., Rue L., Xifro X., Xu J., Ortega Z., Lucas J.J., Lombroso P.J., Alberch J., Perez-Navarro E. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J. Neurosci. 2011, 31:8150-8162.
84. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
85. Shumway S.D., Maki M., Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. J. Biol. Chem. 1999, 274:30874-30881.
86. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8:1051-1058.
87. Snyder E.M., Philpot B.D., Huber K.M., Dong X., Fallon J.R., Bear M.F. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat. Neurosci. 2001, 4:1079-1085.
88. Spencer M.L., Theodosiou M., Noonan D.J. NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif. J. Biol. Chem. 2004, 279:37069-37078.
89. Turalba A.V., Leite-Morris K.A., Kaplan G.B. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci. Lett. 2004, 357:53-57.
90. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:491-496.
91. Van den Oever M.C., Spijker S., Smit A.B. The synaptic pathology of drug addiction. Adv. Exp. Med. Biol. 2012, 970:469-491.
92. Watanabe Y., Shiozuka K., Ikeda T., Hoshi N., Hiraki H., Suzuki T., Hashimoto S., Kawashima H. Cloning of PCPTP1-Ce encoding protein tyrosine phosphatase from the rat cerebellum and its restricted expression in Purkinje cells. Brain Res. Mol. Brain Res. 1998, 58:83-94.
93. Xu J., Chatterjee M., Baguley T.D., Brouillette J., Kurup P., Ghosh D., Kanyo J., Zhang Y., Seyb K., Onomenyi C., Foscue E., Anderson G.M., Gressack J., Cuny G.D., Glicksman M.A., Greengard P., Lam T., Nairn A.C., Tautz L., Ellman J.A., Lombroso P.J. Inhibitors of the tyrosine phosphatase STEP reverse cognitive deficits in a mouse model of Alzheimer's disease. PLoS Biol. 2014, 12:e1001923.
94. Xu J., Kurup P., Bartos J.A., Patriarchi T., Hell J.W., Lombroso P.J. Striatal-enriched protein-tyrosine phosphatase (STEP) regulates Pyk2 kinase activity. J. Biol. Chem. 2012, 287:20942-20956.
95. Xu J., Kurup P., Zhang Y., Goebel-Goody S.M., Wu P.H., Hawasli A.H., Baum M.L., Bibb J.A., Lombroso P.J. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J. Neurosci. 2009, 29:9330-9343.
96. Yang C.H., Huang C.C., Hsu K.S. A critical role for protein tyrosine phosphatase nonreceptor type 5 in determining individual susceptibility to develop stress-related cognitive and morphological changes. J. Neurosci. 2012, 32:7550-7562.
97. Zalfa F., Giorgi M., Primerano B., Moro A., Di Penta A., Reis S., Oostra B., Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003, 112:317-327.
98. Zhang L., Xie J.W., Yang J., Cao Y.P. Tyrosine phosphatase STEP61 negatively regulates amyloid beta-mediated ERK/CREB signaling pathways via alpha7 nicotinic acetylcholine receptors. J. Neurosci. Res. 2013, 91:1581-1590.
99. Zhang Y., Kurup P., Xu J., Anderson G.M., Greengard P., Nairn A.C., Lombroso P.J. Reduced levels of the tyrosine phosphatase STEP block beta amyloid-mediated GluA1/GluA2 receptor internalization. J. Neurochem. 2011, 119:664-672.
100. Zhang Y., Kurup P., Xu J., Carty N., Fernandez S.M., Nygaard H.B., Pittenger C., Greengard P., Strittmatter S.M., Nairn A.C., Lombroso P.J. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19014-19019.
101. Zhang Y., Venkitaramani D.V., Gladding C.M., Zhang Y., Kurup P., Molnar E., Collingridge G.L., Lombroso P.J. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J. Neurosci. 2008, 28:10561-10566.